Cardiovascular morbidity and mortality in acromegaly-associated diabetes: a Swedish Nationwide study

Clicks: 2
ID: 324580
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #136 of 359 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 359 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CONTEXT: Secondary diabetes mellitus occurs in 30-50% of patients with acromegaly despite a lean phenotype, whereas type 2 diabetes mellitus (T2DM) is associated with adiposity. OBJECTIVE: We compared mortality, morbidity and treatment patterns between patients with acromegaly-associated diabetes (ACRO-DM) and T2DM. DESIGN: Nationwide, retrospective, matched-cohort study in Sweden. METHODS: The ACRO-DM group included patients with an acromegaly diagnosis in the Patient Register, with diabetes registered in the National Diabetes Register (NDR) or a dispensed glucose-lowering drug in the Prescribed Drug Register. Controls with T2DM from the NDR were matched 10:1 for sex, age, calendar year, diabetes duration. We derived mortality and morbidity outcomes from the Death and Patient Registers. RESULTS: We included 348 patients with ACRO-DM and 3,480 with T2DM. Mean (SD) age was 60.3 (13.2) and 59.5 (15.6) years while diabetes duration was 2.8 (5.8) and 3.0 (7.1) years in ACRO-DM and T2DM, respectively. Baseline cardiovascular morbidity was more common in ACRO-DM than T2DM group (61% vs 43%), including hypertension (48% vs 29%), heart failure (11% vs 5%), arrhythmia (13% vs 9%) and stroke (8% vs 5%).The hazard ratio (HR) for overall mortality was 1.18 (95% CI, 0.96-1.46) in ACRO-DM compared with T2DM group. The ACRO-DM group had a higher risk of cardiovascular morbidity (HR 1.55; 95% CI, 1.24-1.94), with increased hazards for venous thromboembolism, specifically pulmonary, and arrhythmia, whereas cardiovascular mortality was not increased (HR 1.12; 95% CI, 0.78-1.60). CONCLUSIONS: The risk of cardiovascular morbidity was increased in patients with ACRO-DM compared to T2DM.
Reference Key
openalex_W7202119158 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Angelo Milioto, Óskar Ragnarsson, Diego Ferone, Martin Adiels, J Gustav Smith, Annika Rosengren, Gudmundur Johannsson, Daniela Espósito
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag322
URL
https://doi.org/10.1210/clinem/dgag322
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.